Skip to main content

Advertisement

Log in

Genetics and Breast Cancer – Oncologists Perspectives

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Breast cancer is the most common cancer in women worldwide. The clinical outcomes of which, have improved in the past decade, primarily due early diagnosis and multimodal management. Understanding of the disease biology with findings from omics-based research and molecular genetic characterization of the disease has been an important component of the therapy in the past 10 years. There is a need to understand the variations in individuals at the molecular level to enable in sub-classification of the different disease phenotypes and if possible to tailor the treatment to the patient. This article attempts to review the beneficial role of genetics in various facets of breast cancer management, in modern scientific medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent and Ahmedin Jemal (2015) Global cancer statistics, 2012: CA Cancer J Clin: Volume 65, Issue 2, pages 87–108

  2. http://www.nccn.org/professionals/physician_gls/recently_updated.asp

  3. Goldhirsch A, Ingle JN, Gelber RD, et al. (2009) Thresholds for therapies: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol;20:1319–1329.

  4. Aka JA, Mazumdar M, Chen CQ, Poirier D, Lin SX (2010) 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol 24(4):832–845

  5. Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, Zhou M (2010) Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol 6(9):485–493 Review

  6. Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL (2012) Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer 106(5):916–922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Allison KH (2012) Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol 138:770–780

    Article  CAS  PubMed  Google Scholar 

  8. Jonat W, Arnold N (2011) Is the Ki-67 labelling index ready for clinical use? Ann Oncol 22:500–502

    Article  CAS  PubMed  Google Scholar 

  9. Perou CM (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  10. Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sorlie T, Tibshirani R, Parker J, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Goldstein R, Sosabowski J, Vigor K, Chester K, Meyer T (2013) Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther 13(3):359–373

    Article  CAS  PubMed  Google Scholar 

  13. Lisa Hutchinson (2015) CtDNA—identifying cancer before it is clinically detectable: Nat Rev Clin Oncol doi:10.1038/nrclinonc.2015.77: Published online 21 April 2015

  14. Laura Katherine Austin, Paolo Fortina, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta, AmirAli Talasaz, Massimo Cristofanilli; Thomas Jefferson (2014) Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC). J Clin Oncol 32:5 s,(suppl; abstr 11093)

  15. Roschewski M et al. (2015) Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. doi:10.1016/S1470-2045(15)70106-3

    PubMed  Google Scholar 

  16. Kaboli PJ, Rahmat A, Ismail P Ling KH (2015) MicroRNA-based therapy and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res 6

  17. Aloraifi F, Boland MR, Green AJ, Geraghty JG (2015) Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer. Surg Oncol;24(2):100–109

  18. Daly B, Olopade OI (2015) a perfect storm: how tumor biology, genomics, and healthcare delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin 65(3):221–238

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Radheshyam Naik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naik, R., Veldore, V.H. & Gopinath, K.S. Genetics and Breast Cancer – Oncologists Perspectives. Indian J Surg Oncol 6, 415–419 (2015). https://doi.org/10.1007/s13193-016-0491-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0491-7

Keywords

Navigation